BIO-Europe® will take place in Cologne, Germany, from 9 to 11 November 2026, with more than 6,000 senior leaders from biotech, pharma, investment and strategic organisations across Europe, North America and Asia due to attend. Building on more than three decades of collaboration, the 2026 event is described by its organisers as an expansion beyond […]
Researchers report in Science that a new AI system, RFdiffusion3, has designed from scratch enzymes that break down a toxic organophosphate and cleave a fragment of a protein linked to amyloid disease, offering a more precise route to custom biocatalysts.
CN Bio has announced the full scientific programme for its ‘From Insight to Decision’ e-symposium, an online event on organ-on-a-chip (OOC) technology. It will take place on 2 and 8 December 2026. The Cambridge, UK-based company said the sessions will offer practical guidance on using OOC within existing research and development strategies.
Inceptua Group, a provider of clinical trial supply, related services and early access programmes, has acquired SupplyRx, Inc., a US-based company offering cloud-based digital tools for clinical trial pharmacy programmes in the US and Canada. Inceptua is backed by Vesey Street Capital Partners, and financial terms were not disclosed.
London-based Big Picture Bio Ltd has been founded to identify, design and optimise cancer combination therapies. It uses a generative world model of how tumours, immune cells and surrounding tissue interact across disease sites and patient subgroups. The company, which announced its launch on 17 September 2026, pairs AI-driven modelling with targeted wet lab validation. […]
Google DeepMind scientists have embedded detectable provenance watermarks in AI-designed protein binders and in AlphaFold 3 biomolecular structure predictions. Surface plasmon resonance measurements showed that watermarked binders bound three therapeutically relevant targets with affinity comparable with unmarked designs, although the authors caution that the sequence watermark can be removed and that the approach remains only […]
A new dried whole blood protocol allows Zika virus and hepatitis C virus RNA to be amplified and detected without extraction, purification or a centrifuge. Using a portable heater and a low-cost, palm-sized fluorescence reader, University of Illinois Urbana-Champaign researchers detected both viruses at low concentrations in whole blood, with the workflow taking around two […]
Neurizon® Therapeutics Limited has announced that the Sean M. Healey & AMG Center for ALS at Mass General Brigham (Healey & AMG Center) has been awarded a multimillion-dollar, multi-year grant by the US National Institutes of Health (NIH). The funding will support an expanded access protocol (EAP) for NUZ-001, the Melbourne, Australia-based company’s lead investigational […]
Turbine, a virtual biology company, has expanded its collaboration with Daiichi Sankyo after completing an initial feasibility programme that evaluated its predictive modelling capabilities for antibody-drug conjugate (ADC) development.
Laverock Therapeutics, a London-based biotechnology company developing disease-responsive advanced therapies, has announced in vivo programmes spanning CAR-T and genetic medicine. The programmes add to the company’s existing work in ex vivo cell therapies and broaden the range of indications it can address in oncology and genetic disease.